Blarcamesine

N/A

Report date: 2023/12/20 15:34:11
NME

Base Information

Drug NameBlarcamesine
Drug Alias NameBlarcamesine hydrochlorideAE-37 hydrochlorideANAVEX 2-73ANA001-HCl
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSigma opioid receptor agonistsMuscarinic acetylcholine receptor M1 agonistsApoptosis stimulants +[4] 
TargetsSigma opioid receptorMuscarinic acetylcholine receptor M1
Therapy Area/IndicationsRett SyndromeAlzheimer DiseaseParkinson Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesAnavex Life Sciences Corp
China Registration ClassN/A

Develop Information

Active CompaniesAnavex Germany GmbhAnavex Australia Pty LtdAnavex Life Sciences Corp +[4] 
Inactive CompaniesN/A
Active IndicationsRett SyndromeAlzheimer DiseaseParkinson Disease
Inactive IndicationsParkinsonian Disorders

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG